FindTrial
Sign In

A 76-WEEK, WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH CORONARY HEART DISEASE (CHD) OR CHD RISK- EQUIVALENT DISEASE: EVALUATION OF PLASMA ANACETRAPIB CONCENTRATIONS, LIPID LEVELS AND PREGNANCY OUTCOMES (WOMEN OF CHILD-BEARING POTENTIAL) IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH ANACETRAPIB

A 76-WEEK, WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH CORONARY HEART DISEASE (CHD) OR CHD RISK- EQUIVALENT DISEASE: EVALUATION OF PLASMA ANACETRAPIB CONCENTRATIONS, LIPID LEVELS AND PREGNANCY OUTCOMES (WOMEN OF CHILD-BEARING POTENTIAL) IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH ANACETRAPIB

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-056-13
Enrollment
16
Registered
2013-12-11
Start date
2014-01-02
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

MERCK SHARP & DOHME PERU S.R.L.,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. DEFINE study patients who took at least one dose of anacetrapib and are not currently enrolled in the ongoing PN 019-12 study. 2. Patients who have completed or discontinued from the PN 019-12 study. 3. Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.

Exclusion criteria

Exclusion criteria: Please refer to the Study Design

Countries

Australia, Austria, Canada, China, Colombia, Finland, France, Germany, Hungary, Israel, Malasya, Mexico, Netherlands, New Zealand, Norway, Russian Federation, Spain, Sweden, United States

Contacts

Public ContactNelva Garcia

MERCK SHARP & DOHME PERU S.R.L

nelva.garcia.coral@merck.com411-5187

Outcome results

None listed

Source: REPEC (via WHO ICTRP)